Editorial Board Members

The Hepatitis Drug Interactions website was launched in 2010. The website team is based at the University of Liverpool and has responsibility to constantly monitor and update the site’s content.

The Editorial Board provides oversight, strategic vision and direction for the site. It also advises on developmental opportunities and the interface with end users. Biographical details are available for the members by clicking on the photos.

David Back

Liverpool - Chair

Biography

David Back is Professor (Emeritus) of Pharmacology at the University of Liverpool and has worked in the area of pharmacokinetics and drug-drug interactions for more than 30 years. He established the Liverpool HIV Pharmacology Group (LHPG) in 1987 and subsequently the Liverpool group has been at the forefront of pharmacological research of anti-HIV drugs. Currently there are numerous ongoing pharmacokinetic, pharmacogenetic and molecular- based studies involving local, national and international collaborations.

David has authored ~450 publications. He is a former Editor of the British Journal of Clinical Pharmacology and is on the Editorial Board of numerous journals. In 2007 he was awarded the Lilly Prize from the British Pharmacological Society for outstanding contribution to Clinical Pharmacology and in 2015 a Lifetime achievement award from EACS.

Saye Khoo

Liverpool - Website Team

Biography

Saye Khoo is a Professor of Clinical Pharmacology at the University of Liverpool and Honorary Consultant Physician in Infectious Diseases.

Professor Khoo is actively involved in HIV service development locally and nationally. Research interests centre on the pharmacology of HIV treatment failure. This includes the role of therapeutic drug monitoring, population pharmacokinetic modelling, investigation of drug interactions, molecular characterisation of drug metabolism and disposition pathways and the role of host genetic variability in influencing drug exposure and response. There is also a focus on HIV therapy in resource-poor settings, and the pharmacology of anti-tuberculous therapy.

He currently serves on the British HIV Association Treatment Guidelines Committee, the PENTA Pharmacology Steering Group, and is on the editorial board of several journals.

Sara Gibbons

Sara Gibbons is a Clinical Scientist who obtained a degree in Biomedical Sciences from Liverpool John Moores University, followed by an MPhil in Pharmacology from the University of Liverpool.

Sara has been involved with research into the pharmacology of HIV drugs since the early 1990s and with this drug interaction website since its inception. Sara currently administers the site and manages and updates its content.

Fiona Marra

Glasgow - Website Team

Biography

Fiona is a Senior Pharmacist for HCV/HIV at Gartnavel hospital, Glasgow as well as National Advanced Pharmacist for Paediatric HIV in Scotland. She has a Masters Degree in Pharmacy and gained her interest in Infectious Disease when living in West Africa. Fiona is a contributor to SIGN (Scottish Intercollegiate Guidelines Network) on HCV and is currently part of the team expanding the Hepatitis website. She has an interest in Travel/Tropical Medicine having completed Diplomas in International Development and also Travel Medicine. Fiona sits on the board of the Scottish Malaria Group and the Faculty of Travel Medicine in the Royal College of Physicians and Surgeons Glasgow and is currently undergoing a subsequent Masters on Advanced Pharmacy.

David Burger

Radboud University, Nijmegen, The Netherlands

Biography

Professor Burger has been an Associate Professor of Clinical Pharmacology at the Radboud University Nijmegen since October 2002. He received his Pharmacy Degree at the Utrecht University in 1990 and completed his PhD thesis, titled “Bio-analysis and clinical pharmacokinetics of antiretroviral agents in HIV-infected individuals” at the Slotervaart Hospital, Amsterdam, in 1994. The topics of his interest are drug-drug interactions, pediatric pharmacology, therapeutic drug monitoring and operational research in resource-limited countries, and he is (co-)author of more than 350 publications in these fields.

Douglas Dieterich

Mount Sinai School of Medicine, New York

Biography

Professor Dieterich is currently Professor of Medicine in the Division of Liver Diseases and also Director of Continuing Medical Education in the Department of Medicine at Mount Sinai School of Medicine, New York, NY. He has a triple appointment in the divisions of Liver Disease, Gastroenterology, and Infectious Diseases. He graduated from Yale University and received his Doctorate of Medicine from New York University of Medicine. Professor Dieterich has served on several committees of the AIDS Clinical Trials Group at the National Institutes of Health and is an investigator for many ongoing clinical trials evaluating the safety and efficacy of new antiviral treatments for chronic hepatitis B & C.

Graham Foster

London - BASL Representative

Biography

Professor Foster is the Professor of Hepatology at Queen Mary, University of London and a consultant hepatologist at Barts and The London NHS Trust. He trained in Medicine at Oxford and London Universities in the 1980s and completed a PhD in Molecular Biology in 1992 and has published widely in the field of viral liver disease. He is currently President of the British Association for the Study of the Liver (BASL) and founded the British Viral Hepatitis Group.

Jennifer Kiser

University of Colorado, Denver

Biography

Jennifer Kiser is an Assistant Professor at the University of Colorado Denver. She earned her PharmD from the University of North Carolina at Chapel Hill and completed a residency at the University of California San Diego Medical Center and fellowship at the University of Colorado Denver. Her research interests are determining concentration-effect relationships and investigating drug-drug interactions for antiviral drugs. Dr. Kiser’s laboratory is a leader in the development of state of the art analytical methods to quantitate antiviral drug concentrations in various biologic matrices. She is involved in several local, national, and international antiviral clinical pharmacology studies in persons with viral hepatitis and HIV.

Fabien Zoulim

Lyon - EASL Representative

Biography

Professor Zoulim has been a Professor of Medicine at Lyon I University since 1997 and is currently Medical Director of the Hepatology Department at the Hospices Civils de Lyon, and Scientific Director of the Department of Immunology and Virology of INSERM Unit 1052 where he is leading the team on ‘Antiviral therapy of viral hepatitis’. He obtained his MD in Gastroenterology and Hepatology in Lyon Medical School in 1991 and has a PhD in Molecular and Cellular Biology. Professor Zoulim is a member of the Governing Board of the European Association for the Study of the Liver (EASL).